HER2 Heterogeneity in Gastric Cancer: A Comparative Study, Using Two Commercial Antibodies

BACKGROUND: Although amplification of the gene encoding human epidermal growth factor receptor 2 (HER2) is used as an indicator for response to trastuzumab, the reported response rate is low, and few patients with gastric cancer (GC) benefit from this individualized therapy. The aim of this study wa...

Descripción completa

Detalles Bibliográficos
Autores principales: Satala, Catalin Bogdan, Jung, Ioan, Stefan-van Staden, Raluca Ioana, Kovacs, Zsolt, Molnar, Calin, Bara, Tivadar, Fulop, Zsolt Zoltan, Gurzu, Simona
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7596543/
https://www.ncbi.nlm.nih.gov/pubmed/33144857
http://dx.doi.org/10.1155/2020/8860174

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7596543/
https://www.ncbi.nlm.nih.gov/pubmed/33144857
http://dx.doi.org/10.1155/2020/8860174

Ejemplares similares